MCL Literature Feed

This review clarifies updated WHO-5 diagnostic criteria for high-grade B-cell lymphoma, emphasizing the crucial pathologic and genetic distinction from blastoid mantle cell lymphoma to ensure correct patient management.

This review details the evolution of BTK inhibitors from discovery to clinical use in MCL, covering first-generation agents like ibrutinib and newer agents designed to overcome resistance.

This review summarizes the evolution of BTK inhibitors, highlighting how next-generation agents like pirtobrutinib offer improved selectivity, reduced toxicity, and options to overcome resistance in MCL.

This review summarizes the expanding role of T-cell directing immunotherapies, like bispecifics and CAR-T, in treating relapsed/refractory NHL, providing a framework for their application in MCL.

This case series identifies a rare intrasinusoidal bone marrow involvement pattern in MCL, highlighting a key diagnostic pitfall for pathologists and expanding the disease's recognized histopathological spectrum.

This review outlines emerging therapeutic strategies, including non-covalent BTKis, CAR-T, and bispecifics, for managing the clinically challenging population of MCL patients relapsing after covalent BTK inhibitors.

This review highlights using geriatric assessments to guide therapy selection and proactively manage toxicities in older MCL patients, aiming to optimize outcomes and avoid over- or undertreatment.

This review summarizes how BTKi integration into frontline therapy (TRIANGLE trial) challenges the role of transplant, while CAR-T cells are established as the best option after BTKi failure.

This review summarizes the genomic, molecular, and pathological variations in MCL, highlighting how this biological heterogeneity impacts risk stratification, prognosis, and the development of personalized therapies.

This systematic review finds all AI models for lymphoma histopathology, including MCL, have a high risk of bias, questioning their reported high accuracy and current clinical readiness.

A case of TP53-mutated, indolent non-nodal MCL suggests this high-risk marker may not mandate immediate therapy in this specific subtype, supporting a watch-and-wait approach.

This comprehensive review outlines evolving frontline MCL strategies, highlighting the integration of targeted agents, re-evaluation of transplant, and the emerging role of MRD-guided therapy to improve outcomes.

This review details intrinsic (NF-κB, apoptosis, DNA repair) and extrinsic (tumor microenvironment) resistance mechanisms, identifying new therapeutic vulnerabilities to guide personalized strategies for high-risk MCL patients.

This review summarizes current and emerging therapies for relapsed/refractory MCL, highlighting key strategies like BTKi/BCL2i combinations, CAR-T, and bispecific antibodies for this poor-prognosis population.

This review synthesizes clinical, molecular, and genomic markers to define high-risk MCL, guiding risk-stratified treatment and highlighting future therapies like bispecifics for this poor-prognosis population.

This editorial introduces a review series on mantle cell lymphoma, framing the rapid evolution of the treatment landscape from chemotherapy to novel targeted and cellular therapies.

This review contextualizes CAR-T therapy's established role in relapsed/refractory MCL, summarizing universal challenges such as toxicity, access, cost, and the need for effective salvage treatments post-progression.

This review clarifies that cyclin D1-negative MCL is driven by CCND2 or CCND3 translocations, proposing new terminology to improve diagnostic accuracy for this rare and often missed subtype.

This review summarizes how second-generation BTK inhibitors like zanubrutinib offer improved target selectivity and tolerability over first-generation agents, providing a potentially safer therapeutic option for MCL patients.

This review advocates for using prognostic tools like MIPI and TP53 status to guide risk-adapted therapy in MCL, intensifying for high-risk and de-escalating for low-risk patients.

This review outlines management strategies for delayed complications of CAR T-cell therapy in MCL, moving beyond acute CRS and ICANS to improve long-term patient care and outcomes.

This review highlights stereotyped B-cell receptors in MCL, suggesting common antigen-driven pathways that could provide a basis for molecular subclassification to refine patient risk stratification.

The Australasian Lymphoma Alliance provides consensus guidelines for MCL diagnosis and management, integrating novel therapies and risk-stratification using biomarkers like TP53, blastoid morphology, and high Ki67.

This review of PROTAC design outlines a novel protein degradation technology with potential to overcome resistance to targeted therapies like BTK inhibitors in mantle cell lymphoma.

This case report details persistent cytokine release syndrome in an MCL patient after glofitamab, highlighting a rare, severe toxicity profile requiring vigilant management beyond standard CRS protocols.

This case report identifies a novel jumping translocation of 3q in an MCL patient, linking this rare cytogenetic event to clonal evolution and a potential poor prognosis.

This case report details an exceptionally rare extranodal MCL presentation in the lacrimal drainage system, emphasizing its inclusion in the differential diagnosis for masses in this location.

This review outlines the potential of AI-based PET/CT radiomics to improve lymphoma diagnosis and prognosis, but its specific clinical application in MCL remains undefined pending further research.

Spontaneous splenic rupture is a rare but life-threatening initial presentation of MCL, requiring emergency splenectomy which can lead to the diagnosis, as highlighted by this case report.

This general review contextualizes CAR T-cell therapy, including its approved use in mantle cell lymphoma, within the broader landscape of cellular therapies, summarizing its efficacy and common toxicities.